-
Dimension Bio Appoints Biotech Veteran Heidi Hagen to Board of Directors
03 Jun 2025 16:40 GMT
… -- Dimension Bio, a biotechnology company pioneering regenerative therapeutics … infrastructure for PROVENGE®, the first FDA-approved autologous … into meaningful new treatment options for patients.… generation of regenerative medicine with its proprietary …
-
What to know about the success rate for immunotherapy for prostate cancer
29 May 2025 10:53 GMT
… is not a first-line treatment for prostate cancer. Healthcare professionals typically … ’s overall health.
Sipuleucel-T (Provenge)
This is a cancer vaccine … .
Immune checkpoint inhibitors
These drugs, which doctors may also call immunomodulators, work …
-
Yolo group helps men live with prostate cancer
28 May 2025 14:35 GMT
… tested early and follow recommended treatment.
Prostate cancer is one of the … by the FDA is a vaccine called Provenge, according to medical journals. The … questions to ask a doctor about prostate cancer
I want to know …
-
Special Report: New strategies emerge for metastatic prostate cancer
23 May 2025 18:57 GMT
… novo metastatic hormone-sensitive prostate cancer and the treatment landscape for men … high-volume disease who are medically fit, triplet therapy that … sipuleucel-T [Provenge]), radiopharmaceuticals like radium-223 (Xofigo), and prostate-specific membrane …
-
Translating Transfusion-Medicine Technology to Cancer-Vaccine Manufacturing: A Novel Immunization Approach Based on Inactivated Autologous Tumor Cells
08 May 2025 12:24 GMT
… he cofounded Navigant Biotechnologies, which sought … Food and Drug Administration (FDA) clearance on … detection.
Increasing Treatment Availability and Affordability … Provenge (sipuleucel-T): Immunotherapy for Advanced Prostate Cancer. Dendreon Pharmaceuticals …
-
The future of NSCLC treatment: what’s in store for the therapeutic space?
30 Apr 2025 14:10 GMT
… ” in a trial in patients with nonsquamous NSCLC.
NSCLC treatments: tyrosine kinase … South Korean pharmaceutical Yuhan, which retains the rights of the drug in … prostate cancer vaccine Provenge’s footsteps – the first cancer vaccine to receive FDA …
-
PSMA RLT: A Private Medical Oncology Delivery Model "Presentation" - Luke Nordquist
21 Apr 2025 08:16 GMT
… Transcript
Luke Nordquist: --private medical oncology practices and their role … get burned on a PROVENGE or one dose of … be an innovative prostate cancer clinical trials center that had … this, though, is that pharmaceutical companies have back-end templates …
-
Personalized Cancer Vaccine Market Opportunity & Clinical Trials Outlook 2025 - Over 18 Personalized Cancer Vaccines in Clinical Trials Globally - ResearchAndMarkets.com
02 Apr 2025 18:43 GMT
… Approved Personalized Cancer Vaccine: Provenge
Provenge Patent, Price & … the precision medicine revolution, which tailors treatments to … its collaboration with pharmaceutical giant Genentech to …
CureVac AG
Evaxion Biotech
Geneos Therapeutics
Genentech …
-
Personalized Cancer Vaccines Clinical Trials Market Opportunity Technology Platform Insight
25 Mar 2025 07:50 GMT
… Commercially Approved Personalized Cancer Vaccine: Provenge
Provenge Patent , Price & … trials Personalized cancer vaccines represent a revolutionary approach to cancer treatment … immunity, offering a proactive treatment strategy. This personalized …
-
Top Growth Driver In The Provenge Market 2025: Rising Prostate Cancer Prevalence To Drive Growth In The Market
12 Mar 2025 12:52 GMT
… medicine, enhancing treatment outcomes.
oExpansion of clinical trials … drug development.
oEscalating healthcare expenditure, improving treatment … the Provenge Market?
Dendreon Pharmaceuticals LLC … awareness of prostate cancer treatments.
oStrong healthcare …